In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice

Blood

Volumn 97, Issue 5, 2001, Pages 1474-1482

  Pawlowska, Anna B ^b   Hashino, Satoshi ^b   McKenna, Hilary ^b   Weigel, Brenda J ^b   Taylor, Patricia A ^b   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; LEUKEMIA ANTIGEN; TUMOR VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE;

EID: 0035282905     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1474     Document Type: Article

References (61)

1. Time-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group
2. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long-term follow-up and results
3. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Children's Cancer Group study
4. Allogeneic bone marrow transplantation for acute non-lymphocytic leukemia in first remission
5. Randomized comparison of cyclophosphamidetotal body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia
6. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first remission or in second complete remission
7. Graft-versus-leukemia reactions after bone marrow transplantation
8. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
9. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
10. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells. B7 costimulation, and T helper cell 1-associated cytokines
11. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors
12. Vaccination of melanoma patients with peptide- or tumor lysate-pulse dendritic cells
13. Dendritic cells as immunogens for human CTL responses
14. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
15. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: A feasibility study
16. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
17. Dendritic cell development and maturation
18. Dendritic cell-based immunotherapy of prostate cancer
19. Dendritic cell based therapy of cancer
20. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
21. Dendritic cells
22. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
23. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells
24. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro
25. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factors
26. Nat Med
27. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
28. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
29. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
30. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
31. Hematologic effects of flt3 ligand in vivo in mice
32. Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice
33. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: Implications for anticancer and antiviral therapy
34. Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: Definition of cytokine requirements and developmental intermediates
35. FLT3-ligand administration inhibits liver metastases: Role of NK cells
36. Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells
37. Single adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells
38. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interteukin-15
39. Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia
40. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer
41. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
42. The JAM test: A simple assay for DNA fragmentation and cell death
43. Limiting dilution assays for the determination of immunocompetent cell frequencies. I: Data analysis
44. Absence of a facilitory role for NK 1.1-positive donor cells in engraftment across a major histocompatibility barrier in mice
45. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome
46. Induction of dendritic cells by Flt3 ligand promotes the generation of tumor-specific immune responses in vivo
47. Antileukemic activity of Flt3 ligand in murine leukemia
48. Dendritic cells directly trigger NK cell functions: Crosstalk relevant in innate anti-tumor immune responses in vivo
49. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
50. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells
51. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help
52. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
53. Effects of human FLT3 ligand on myeloid leukemia cell growth: Heterogeneity in response and synergy with other hematopoietic growth factors
54. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
55. Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children
56. Ex vivo cytokine expansion of peripheral blood Ph-negative cells in chronic myeloid leukaemia
57. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells
58. Failure of T cell receptor-anti-CD3 monoclonal antibody interaction in T cells from marrow recipients to induce increases in intracellular ionized calcium
59. Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow
60. Immune reconstitution following bone marrow transplantation: Comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts
61. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia